Results 41 to 50 of about 4,362 (171)

Lipodistrofia parcial adquirida y glomerulopatía C3: la desregulación del sistema del complemento como mecanismo común

Nefrología, 2018
Resumen: La activación de la vía alternativa del complemento interviene en el desarrollo de varias enfermedades renales, como el síndrome hemolítico urémico atípico o la glomerulopatía C3.
Fernando Corvillo, Margarita López-Trascasa   +1 more
doaj   +1 more source

C3 glomerulopathy: consensus report [PDF]

Kidney International, 2013
C3 glomerulopathy is a recently introduced pathological entity whose original definition was glomerular pathology characterized by C3 accumulation with absent or scanty immunoglobulin deposition. In August 2012, an invited group of experts (comprising the authors of this document) in renal pathology, nephrology, complement biology, and complement ...
Pickering, MC, D'Agati, VD, Nester, CM, Smith, RJ, Haas, M, Appel, GB, Alpers, CE, Bajema, IM, Bedrosian, C, Braun, M, Doyle, M, Fakhouri, F, Fervenza, FC, Fogo, AB, Fremeaux-Bacchi, V, Gale, DP, De Jorge, EG, Griffin, G, Harris, CL, Holers, VM, Johnson, S, Lavin, PJ, Medjeral-Thomas, N, Morgan, BP, Nast, CC, Noel, L-H, Peters, DK, Rodriguez de Cordoba, S, Servais, A, Sethi, S, Song, W-C, Tamburini, P, Thurman, JM, Zavros, M, Cook, HT   +34 more
openaire   +5 more sources

Effectiveness of Cyclosporine in a 10-year-old Girl with C3 Glomerulopathy [PDF]

Childhood Kidney Diseases, 2017
C3 glomerulopathy (C3G) is a recently defined pathological entity characterized by C3 accumulation with absent or scant immunoglobulin deposition, leading to variable glomerular inflammation.
Kyung Mi Jang, Yong Hoon Park
doaj   +1 more source

Complement Factor H‐Based Therapeutics: A Comprehensive Overview

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Complement factor H is a central regulator of the complement system and thus a target for therapeutic intervention. In this review, we provide an overview of past and current factor H‐based therapeutic concepts and modalities to treat complement‐mediated diseases.
Sebastiaan M. W. R. Hamers, Emmy J. Buter, Richard B. Pouw   +2 more
wiley   +1 more source

First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders

Journal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.
ABSTRACT This guideline summarizes diagnostic and therapeutic approaches based on a systematic literature review and evidence evaluation using the GRADE methodology. Given the limited high‐quality data, expert consensus was additionally obtained through a modified Delphi process.
Giorgia Olivieri, Andrea Bordugo, Birute Burnyte, Alessandro Costetti, Maria‐Luz Couce, Luisa Diogo, Francois Feillet, D. Sean Froese, Benedetta Greco, Jean‐Louis Gueant, Luciana Hannibal, Friederike Hörster, Viktor Kožich, Giancarlo La Marca, Irini Manoli, Fanny Mochel, Lorenzo Orazi, Belén Pérez, Manuel Schiff, Bernd C. Schwahn, Ida Schwartz, Karolina M. Stepien, Jolanta Sykut‐Cegielska, Trine Tangeraas, Rolf H. Zetterström, Carlo Dionisi‐Vici, Martina Huemer   +26 more
wiley   +1 more source

COQ2‐Associated Primary Coenzyme Q10 Deficiency Presenting With Proteinuria: A Case Report and Literature Review

Molecular Genetics &Genomic Medicine, Volume 14, Issue 7, July 2026.
We report a female pediatric patient with compound heterozygous *COQ2* variants (c.368G>A, c.908A>G) presenting PCOQ10D; high‐dose CoQ10 plus enalapril maleate resolved proteinuria and preserved renal function. ABSTRACT Background Primary coenzyme Q10 (CoQ10) deficiency (PCOQ10D) is an autosomal recessive mitochondrial disorder caused by pathogenic ...
Yuqi Yue, Fei Zhao, Qiuxia Chen
wiley   +1 more source

Treatment options for C3 glomerulopathy [PDF]

Current Opinion in Nephrology and Hypertension, 2013
The purpose of this review is to discuss emerging nomenclature, review the salient clinicopathological features and describe the therapeutic options available for the treatment of C3 glomerulopathy (C3G).C3G is minimally responsive to traditional immune suppression and randomized controlled trials to support therapy are absent.
Carla M, Nester, Richard J, Smith
openaire   +2 more sources

Global Consultation for Clinical Xenotransplantation: International Xenotransplantation Association Consensus and Communiqué Update

Xenotransplantation, Volume 33, Issue 4, July/August 2026.
ABSTRACT Xenotransplantation has entered a phase of accelerated clinical translation, necessitating renewed international consensus on governance, ethics, safety, and regulatory oversight. In September 2025, the International Xenotransplantation Association (IXA), in partnership with The Transplantation Society (TTS) and with engagement from the World ...
Wayne J. Hawthorne, Eckhard Wolf, Peter J. Cowan, Wei Wang, Ik Jin Yun, Paolo Brenner, Greg Korbutt, Raphael P. H. Meier, Megan Sykes, Léo H. Bühler, Linda Scobie, Olga Garkavenko, Hyunil Kim, Daniel J. Hurst, Richard N. Pierson III, Robert Rieben, Manuel Pascual, Nicole Scholes‐Robertson, Emanuele Cozzi, Adrián Abalovich, Alexandre Loupy, Hidetaka Hara, Rita Bottino, Burcin Ekser, Muhammad M. Mohiuddin, Jay Fishman   +25 more
wiley   +1 more source

Complement Inhibitors in Clinical Trials for Glomerular Diseases

Frontiers in Immunology, 2019
Defective complement action is a cause of several human glomerular diseases including atypical hemolytic uremic syndrome (aHUS), anti-neutrophil cytoplasmic antibody mediated vasculitis (ANCA), C3 glomerulopathy, IgA nephropathy, immune complex ...
Peter F. Zipfel, Peter F. Zipfel, Thorsten Wiech, Ramona Rudnick, Sara Afonso, Fermin Person, Christine Skerka   +6 more
doaj   +1 more source

Decoding the Factor H‐Related Proteins: Gatekeepers of Complement Dysregulation in AMD

European Journal of Immunology, Volume 56, Issue 6, June 2026.
This review will explore the role of the factor H‐related (FHR) proteins in age‐related macular degeneration (AMD), their accumulation in the outer blood/retinal barrier, and how they may contribute to barrier dysfunction and inflammation. ABSTRACT Age‐related macular degeneration (AMD) is the third most common form of blindness in the Western world ...
Jiaqi Tang, Nathalie Zgoda, Simon J. Clark   +2 more
wiley   +1 more source